Empowered Funds LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Empowered Funds LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 681.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 62,052 shares of the company’s stock after acquiring an additional 54,114 shares during the period. Empowered Funds LLC owned approximately 0.06% of Neurocrine Biosciences worth $7,150,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of NBIX. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after purchasing an additional 90 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after buying an additional 92 shares during the last quarter. Total Clarity Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 4.3% in the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock valued at $335,000 after acquiring an additional 100 shares during the period. Caprock Group LLC raised its stake in Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock worth $230,000 after acquiring an additional 109 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its position in Neurocrine Biosciences by 2.7% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock worth $496,000 after acquiring an additional 113 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $117.44 on Friday. The business has a 50 day simple moving average of $118.50 and a two-hundred day simple moving average of $132.66. The stock has a market capitalization of $11.89 billion, a P/E ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $107.84 and a 12 month high of $157.98.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Raymond James restated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada dropped their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.